FDA recall D-0514-2026 · initiated Apr 29, 2026
May cause temporary or medically reversible harm; low probability of serious harm.
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.